Shunho Shares Report Strong Growth in 2024 Half-Year Results

Business by 2FIRSTS.ai
Aug.19.2024
Shunho Shares Report Strong Growth in 2024 Half-Year Results
Shanghai Shunho released its 2024 semi-annual report, with a 29.98% revenue increase, focusing on e-cigarette and industrial hemp projects.

On August 17th, Shanghai Shunho New Material Technology Co., Ltd. (Stock abbreviation: Shunho shares, stock code: 002565) released its semi-annual report for the year 2024.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


A report shows that the company achieved operating revenue of approximately 706 million yuan during the reporting period, an increase of 29.98% year-on-year. However, the company's business in the field of new tobacco products has decreased, with operating revenue of 2,700,885.54 yuan, accounting for 0.38% of the total operating revenue of the company, a decrease of 30.65% from the same period last year. This may be due to factors such as changes in market environment, policy adjustments, or company strategic realignments. The operating revenue from e-cigarette projects was 4.66 million yuan, while the industrial hemp project had operating revenue of 83,500 yuan.

Shunho Shares Report Strong Growth in 2024 Half-Year Results


According to reports, Shunho's subsidiary Greencore has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette processing companies in the new tobacco field. Its invested company, Meizhonglian, has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette product manufacturing companies. Meanwhile, Shunho's subsidiary Yilong has obtained the Tobacco Monopoly Production Enterprise License for e-cigarette brand holding companies for domestic sales.


The company stated that its subsidiary Shunho Yilong's "Yilong" brand e-cigarette has been launched in some retail stores in Beijing, Shenzhen, and Shanghai areas, and will continue to promote the listing of "Yilong" products in multiple locations in the future.


In addition, the company's wholly-owned subsidiary Yunnan Lvxin has obtained the "Yunnan Province Industrial Hemp Processing License," which means the company is qualified to process industrial hemp in Qujing City, Yunnan Province. To seize the rapidly growing opportunities in the overseas industrial hemp market, Shunho Corporation has established a subsidiary, Kinneloa Holdings Inc., in the United States. With legal qualifications to carry out industrial hemp processing and manufacturing related business in the US, as well as sales in other legal countries and regions worldwide. Kinneloa Holdings Inc.'s wholly-owned subsidiary, E1011 Labs, has launched ELON second-generation HNB devices and Stelo heating rod products.


Another wholly-owned subsidiary of the company, Vitaldiol Pharmaceutical, has launched the Vitaldiol – R Series (Recover, Relief, Rest) products and Essential elixirs for the US market. These products contain ingredients such as CBD, NMN (Nicotinamide Mononucleotide), turmeric, melatonin, and others, emphasizing a "minimalist ingredients" and "natural health" concept.


The report mentioned that the global e-cigarette market is expected to continue growing, and the company stated that they will increase research and development investment to further expand the new tobacco industry both domestically and overseas.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03